PHARMACOLOGY UPDATE

Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy)

June 15, 2023

Arexvy can be administered to prevent lower respiratory tract disease caused by respiratory syncytial virus in patients age 60 years and older.

Issue Date: June 15, 2023

Table of Contents

Financial Disclosure: Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi; is a retained consultant for AstraZeneca, Novo Nordisk, and Sanofi; and is a stockholder with Paracrine. Dr. Harini Sarva, author, reports she receives grant/research support from Biogen, BlueRock Therapeutics, Covance, Insightec, the National Institutes of Health, NeuroDerm, Novo Nordisk, Prevail Therapeutics, and Roche and is a consultant for BlueRock Therapeutics, Novo Nordisk, and NeuroDerm The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements